TWI725937B - ω-３組成物、劑型及使用方法 - Google Patents
ω-３組成物、劑型及使用方法 Download PDFInfo
- Publication number
- TWI725937B TWI725937B TW104118318A TW104118318A TWI725937B TW I725937 B TWI725937 B TW I725937B TW 104118318 A TW104118318 A TW 104118318A TW 104118318 A TW104118318 A TW 104118318A TW I725937 B TWI725937 B TW I725937B
- Authority
- TW
- Taiwan
- Prior art keywords
- dosage form
- scope
- patent application
- item
- group
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title claims abstract description 88
- 239000000203 mixture Substances 0.000 title abstract description 67
- 238000000034 method Methods 0.000 title abstract description 62
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims abstract description 44
- 150000003626 triacylglycerols Chemical class 0.000 claims abstract description 25
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 54
- 239000000194 fatty acid Substances 0.000 claims description 54
- 229930195729 fatty acid Natural products 0.000 claims description 54
- 150000004665 fatty acids Chemical class 0.000 claims description 52
- 239000003921 oil Substances 0.000 claims description 39
- 235000019198 oils Nutrition 0.000 claims description 39
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 30
- 241000238366 Cephalopoda Species 0.000 claims description 25
- 125000004494 ethyl ester group Chemical group 0.000 claims description 19
- 239000010775 animal oil Substances 0.000 claims description 15
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 14
- 235000021323 fish oil Nutrition 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 8
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 6
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 4
- 230000000284 resting effect Effects 0.000 claims description 4
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 4
- 235000021281 monounsaturated fatty acids Nutrition 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 26
- 239000000902 placebo Substances 0.000 description 33
- 229940068196 placebo Drugs 0.000 description 33
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 32
- 125000004185 ester group Chemical group 0.000 description 25
- 101710095342 Apolipoprotein B Proteins 0.000 description 21
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 230000008859 change Effects 0.000 description 16
- 235000020925 non fasting Nutrition 0.000 description 13
- 230000008569 process Effects 0.000 description 12
- 239000004006 olive oil Substances 0.000 description 11
- 235000008390 olive oil Nutrition 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 241000251468 Actinopterygii Species 0.000 description 8
- 108090001030 Lipoproteins Proteins 0.000 description 8
- 102000004895 Lipoproteins Human genes 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 239000004202 carbamide Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 230000003205 diastolic effect Effects 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- -1 diglycerides Chemical class 0.000 description 5
- 238000002203 pretreatment Methods 0.000 description 5
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 102100032752 C-reactive protein Human genes 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 208000006575 hypertriglyceridemia Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000004061 bleaching Methods 0.000 description 3
- 239000000306 component Substances 0.000 description 3
- DTMGIJFHGGCSLO-FIAQIACWSA-N ethyl (4z,7z,10z,13z,16z,19z)-docosa-4,7,10,13,16,19-hexaenoate;ethyl (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC.CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC DTMGIJFHGGCSLO-FIAQIACWSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940115970 lovaza Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000003441 saturated fatty acids Nutrition 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- 239000006014 omega-3 oil Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000005809 transesterification reaction Methods 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229920000064 Ethyl eicosapentaenoic acid Polymers 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 101710105047 Lipoprotein B Proteins 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000199 molecular distillation Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 108010079522 solysime Proteins 0.000 description 1
- 150000003464 sulfur compounds Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462009145P | 2014-06-06 | 2014-06-06 | |
| US62/009,145 | 2014-06-06 | ||
| US201462019289P | 2014-06-30 | 2014-06-30 | |
| US62/019,289 | 2014-06-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201613571A TW201613571A (en) | 2016-04-16 |
| TWI725937B true TWI725937B (zh) | 2021-05-01 |
Family
ID=54767418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104118318A TWI725937B (zh) | 2014-06-06 | 2015-06-05 | ω-３組成物、劑型及使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9675575B2 (enExample) |
| EP (2) | EP3151826A4 (enExample) |
| JP (2) | JP6755186B2 (enExample) |
| KR (1) | KR102400958B1 (enExample) |
| CN (1) | CN106687113B (enExample) |
| AU (1) | AU2015269307C1 (enExample) |
| BR (1) | BR112016028561A8 (enExample) |
| CA (1) | CA2950344C (enExample) |
| CL (1) | CL2016003131A1 (enExample) |
| MX (1) | MX2016015791A (enExample) |
| MY (1) | MY186566A (enExample) |
| RU (1) | RU2741965C2 (enExample) |
| TW (1) | TWI725937B (enExample) |
| WO (1) | WO2015188046A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10709680B2 (en) * | 2011-07-18 | 2020-07-14 | Physicians Recommended Nutriceuticals, Llc | Methods for treating dry eye |
| AU2015269307C1 (en) * | 2014-06-06 | 2019-10-03 | Marine Ingredients, Llc | Omega-3 compositions, dosage forms, and methods of use |
| CN110958731A (zh) | 2018-09-21 | 2020-04-03 | 鸿盛国际有限公司 | 发光二极管并联电路 |
| FR3103355B1 (fr) | 2019-11-26 | 2024-05-31 | Polaris | Composition d’huile de micro-organismes enrichie en acides gras polyinsaturés |
| FR3151183A1 (fr) | 2023-07-20 | 2025-01-24 | Microphyt | Nouvelle utilisation d’un extrait de la microalgue Phaeodactylum tricornutum |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| FR2731015B1 (fr) | 1995-02-24 | 1997-05-30 | Sci Sartone | Procede d'enrichissement enzymatique d'huiles d'origine marine et les triglycerides d'acides gras polyinsatures ainsi obtenus |
| JP2000501131A (ja) * | 1995-11-24 | 2000-02-02 | ロダース・クロックラーン・ビー・ブイ | 魚油をベースとする組成物 |
| US7799365B2 (en) * | 2001-04-06 | 2010-09-21 | Burnbrae Farms Limited | Liquid egg composition including fish oil with omega-3 fatty acid |
| US7169385B2 (en) * | 2003-09-29 | 2007-01-30 | Ronald G. Udell | Solubilized CoQ-10 and carnitine |
| SE0303513D0 (sv) | 2003-12-19 | 2003-12-19 | Pronova Biocare As | Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
| US20070020340A1 (en) * | 2005-07-25 | 2007-01-25 | David Rubin | Fish oil products for reducing cholesterol, low density lipoprotein, and hypertension |
| CA2625338A1 (en) | 2005-10-07 | 2007-06-14 | Ocean Nutrition Canada Ltd. | Salts of fatty acids and methods of making and using thereof |
| EP2364701A1 (en) | 2005-12-20 | 2011-09-14 | Cenestra, Llc | Omega-3 fatty acid formulations |
| EP3263101A1 (en) | 2005-12-21 | 2018-01-03 | Brudy Technology, S.L. | Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage |
| WO2007149592A2 (en) | 2006-06-23 | 2007-12-27 | The Procter & Gamble Company | Concentrated omega-3 fatty acids and mixtures containing them |
| WO2008036353A2 (en) | 2006-09-19 | 2008-03-27 | The Trustees Of Columbia University In The City Of New York | Omega-3 diglyceride emulsions |
| EP2147088A4 (en) * | 2007-04-26 | 2010-05-05 | Patrick Adlercreutz | FERTILIZED MILK OILS COMPRISING MULTIPLE-UNSATURATED FATTY ACIDS, COMPRISING EICOSAPENTAIC ACID (EPA) AND DOCOSAHEXAIC ACID (DHA), AND MANUFACTURING METHOD THEREFOR |
| US20100119600A1 (en) * | 2007-06-01 | 2010-05-13 | Joar Opheim | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof |
| CL2008002020A1 (es) | 2007-07-12 | 2008-11-14 | Ocean Nutrition Canada Ltd | Metodo de modificacion de un aceite, que comprende hidrolizar gliceridos con una solucion de lipasa thermomyces lanuginosus, separar la fraccion de acido graso saturado de la fraccion de glicerido hidrolizado y esterificar los gliceridos hidrolizados en la presencia de candida antarctica lipasa b; y composicion de aceite. |
| KR101502191B1 (ko) * | 2007-07-30 | 2015-03-12 | 닛폰 스이산 가부시키가이샤 | Ｅｐａ 농축유 및 ｄｈａ 농축유의 제조 방법 |
| KR101045397B1 (ko) | 2008-07-04 | 2011-06-30 | 주식회사동우산업 | 오메가-3 지방산 함량이 높은 정제 오징어유의 제조방법 |
| GB0813599D0 (en) | 2008-07-24 | 2008-09-03 | Pharma Marine As | Method |
| EP2323647B1 (en) * | 2008-08-07 | 2014-09-10 | SPA SOCIETA' PRODOTTI ANTIBIOTICI S.p.A. | Long-term treatment of symptomatic heart failure |
| US20100236137A1 (en) * | 2008-09-23 | 2010-09-23 | LiveFuels, Inc. | Systems and methods for producing eicosapentaenoic acid and docosahexaenoic acid from algae |
| US9532963B2 (en) * | 2009-03-09 | 2017-01-03 | Pronova Biopharma Norge As | Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof |
| CN101695487B (zh) * | 2009-09-22 | 2012-01-18 | 北京百慧生化制药有限责任公司 | 一种高纯度epa-e、dha-e的多烯酸乙酯乳剂 |
| FR2955459B1 (fr) | 2010-01-28 | 2013-11-22 | Polaris | Composition huileuse riche en monoglycerides de dha |
| US20110223246A1 (en) * | 2010-03-10 | 2011-09-15 | Joar Opheim | Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source |
| US9675572B2 (en) | 2010-04-23 | 2017-06-13 | The United States Of America As Represented By The Secretary Of The Army | Intravenous omega-3 fatty acid compositions and method of use |
| CN103221524B (zh) * | 2010-09-24 | 2021-01-01 | 普罗诺瓦生物医药挪威公司 | 用于浓缩omega-3脂肪酸的方法 |
| US20120252888A1 (en) * | 2011-03-29 | 2012-10-04 | Palupa Medical Ltd. | Compositions and Methods for Treating Neurologic Disorders |
| WO2013086323A2 (en) * | 2011-12-08 | 2013-06-13 | Metaproteomics, Llc | Supplemented oil compositions and methods for improved health |
| EP2793867B1 (en) * | 2011-12-22 | 2021-01-20 | Baes, Erik | Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof |
| JP6370775B2 (ja) | 2012-05-10 | 2018-08-08 | ソルテックス エヌエー エルエルシー | 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油 |
| WO2014057362A2 (en) | 2012-09-24 | 2014-04-17 | Aker Biopharma As | Omega -3 compositions |
| US20130310457A1 (en) | 2013-07-25 | 2013-11-21 | Niral Ramesh | Solid-in-oil dispersions |
| AU2015269307C1 (en) * | 2014-06-06 | 2019-10-03 | Marine Ingredients, Llc | Omega-3 compositions, dosage forms, and methods of use |
-
2015
- 2015-06-05 AU AU2015269307A patent/AU2015269307C1/en active Active
- 2015-06-05 MY MYPI2016704514A patent/MY186566A/en unknown
- 2015-06-05 TW TW104118318A patent/TWI725937B/zh active
- 2015-06-05 WO PCT/US2015/034372 patent/WO2015188046A1/en not_active Ceased
- 2015-06-05 RU RU2016149416A patent/RU2741965C2/ru active
- 2015-06-05 KR KR1020167034160A patent/KR102400958B1/ko active Active
- 2015-06-05 EP EP15803689.7A patent/EP3151826A4/en not_active Ceased
- 2015-06-05 CA CA2950344A patent/CA2950344C/en active Active
- 2015-06-05 MX MX2016015791A patent/MX2016015791A/es unknown
- 2015-06-05 JP JP2016569985A patent/JP6755186B2/ja active Active
- 2015-06-05 CN CN201580030195.7A patent/CN106687113B/zh active Active
- 2015-06-05 EP EP21157298.7A patent/EP3906920A1/en not_active Ceased
- 2015-06-05 BR BR112016028561A patent/BR112016028561A8/pt not_active IP Right Cessation
-
2016
- 2016-05-04 US US15/146,680 patent/US9675575B2/en active Active
- 2016-12-05 CL CL2016003131A patent/CL2016003131A1/es unknown
-
2017
- 2017-05-19 US US15/600,124 patent/US10034849B2/en active Active
-
2018
- 2018-06-29 US US16/023,904 patent/US10172819B2/en active Active
-
2019
- 2019-01-04 US US16/240,534 patent/US11160777B2/en active Active
-
2020
- 2020-04-06 JP JP2020068334A patent/JP2020105224A/ja active Pending
Non-Patent Citations (4)
| Title |
|---|
| Am J Clin Nutr 1990,52,p.632-639 * |
| Am J Clin Nutr 1990,52,p.632-639。 |
| Prostaglands,Leukotrienes and Essential Fatty Acids,83(2010),p.137-141 * |
| Prostaglands,Leukotrienes and Essential Fatty Acids,83(2010),p.137-141。 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11160777B2 (en) | Omega-3 compositions, dosage forms, and methods of use | |
| JP2020050675A (ja) | 認知機能改善および心拍数低下のための方法 | |
| UA76108C2 (en) | Use of therapeutic combination of fatty acids | |
| LU87570A1 (fr) | Composition d'acides gras | |
| JP2008525392A (ja) | Ｅｐａによる重度のメランコリー型うつ病の治療 | |
| JP6663993B2 (ja) | 安定性が向上し、取り込みが改善されたホノキオール及びマグノロール製剤、並びにそれらの使用方法 | |
| JP2020182497A (ja) | 一価不飽和脂肪酸組成物およびアテローム性動脈硬化症を処置するための使用 | |
| JPH04290822A (ja) | アレルギー予防薬および食品 | |
| JP2018104372A (ja) | クリルオイルと魚油とシソ油とを含有する組成物 | |
| CN106459833A (zh) | 源自水产物的游离一元不饱和脂肪酸或其低级醇酯的制造方法 | |
| JP4707839B2 (ja) | 糖尿病予防治療剤 | |
| JP6787891B2 (ja) | コミュニケーションスキルの改善のためのリン脂質調製物 | |
| JP3550176B2 (ja) | トコフェロール強化精製エゴマ油、それを含有する脂肪輸液剤及び経口投与製剤 | |
| JPWO2002040014A1 (ja) | 経口用又は経腸用の油脂組成物及びヘキサコサン酸低下剤 | |
| Funk Ms | Select Dietary Fatty Acids Modulate Brain Long Chain Omega-3 and Omega-6 PUFA Content in Mice | |
| BR112020026069B1 (pt) | Composição de lipídio à base de vegetais, uso da mesma, composição nutracêutica, produto alimentício para consumo humano ou animal, e, processo para produzir uma composição de lipídio à base de vegetais | |
| UA124828U (uk) | Купажована рослинна олія | |
| WO1987007263A1 (fr) | Composition contenant un compose de l'acide linolenique | |
| JP2002193798A (ja) | ナチュラルキラー細胞活性化剤 | |
| JP2007297395A (ja) | 高吸収性コエンザイムｑ１０組成物及びその製造方法 |